<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03422419</url>
  </required_header>
  <id_info>
    <org_study_id>IICT2017_PROGRESS</org_study_id>
    <nct_id>NCT03422419</nct_id>
  </id_info>
  <brief_title>TIPS or Anticoagulation in Portal Vein Thrombosis</brief_title>
  <acronym>PROGRESS</acronym>
  <official_title>An Investigator-initiated, Multicentre, Randomized, Trial Comparing Anticoagulation Alone Versus Transjugular Intrahepatic Portosystemic Shunt (TIPS) and Anticoagulation in Patients With Recent Obstructive Portal Vein Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PROGRESS is an investigator-initiated, multicentre, randomized, trial comparing
      anticoagulation, which is the currently most frequently used treatment, alone, versus
      transjugular intrahepatic portosystemic shunt (TIPS) combined with anticoagulation, in
      patients presenting with ROPVT. The rationale of this study is to significantly increase the
      proportion of patients that achieve a complete or partial recanalization of the portal vein.
      The intervention of this study consists in TIPS deployment and catheter based clot removal in
      addition to anticoagulation. The investigators retain that this intervention will increase
      the proportion of patients with an open portal vein from 38% with anticoagulation alone to
      83% with anticoagulation and TIPS after 6 months. Both anticoagulant therapy and clot
      removal/TIPS are treatments that are currently available and accepted indications for the
      treatment of ROPVT. Anticoagulation will be performed with unfractioned heparin or low
      molecular weight heparin initially and with vitamin K antagonists in the long term. The
      investigators plan to collect blood for biobanking at the time of inclusion and after 6
      months. Blood samples for a biobank will be collected.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2018</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with complete recanalization of the portal vein&quot;.</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Thrombosis Portal Vein</condition>
  <arm_group>
    <arm_group_label>TIPS+Anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Anticoagulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>The choice of the anticoagulant medication in terms of duration and dose will be determined by the treating physician.</description>
    <arm_group_label>TIPS+Anticoagulation</arm_group_label>
    <arm_group_label>Anticoagulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TIPS</intervention_name>
    <description>transjugular intrahepatic portosystemic shunt deployment</description>
    <arm_group_label>TIPS+Anticoagulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Recent complete thrombosis of the extrahepatic portal vein either with or without the
             involvement of intrahepatic branches and with or without involvement of splenic vein
             and superior mesenteric vein

          2. Written informed consent

        Exclusion Criteria:

          1. Malignant PV thrombosis (neoplastic invasion)

          2. Intraabdominal malignancy

          3. Chronic diseases limiting life expectancy in the short term (6 months)

          4. Liver transplantation

          5. Unwillingness to participate

          6. Contraindications to TIPS (including past or present hepatic encephalopathy Grade â‰¥2)

          7. Child-Pugh-Turcotte score 11 or more points in patients with advanced chronic liver
             disease-
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea De Gottardi, Prof. Dr. med</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Inselspital, Berne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea De Gottardi, Prof. Dr. med</last_name>
    <phone>42 (0) 31 632</phone>
    <phone_ext>38 13</phone_ext>
    <email>Andrea.DeGottardi@insel.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eugenia Mc Allister, Dr.sc.</last_name>
    <phone>41 (0) 31 632</phone>
    <phone_ext>87 28</phone_ext>
    <email>eugenia.mcallister@insel.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <state>BE</state>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea De Gottardi, Prof. Dr. med.</last_name>
      <phone>41 (0) 31 632</phone>
      <phone_ext>38 13</phone_ext>
      <email>Andrea.DeGottardi@insel.ch</email>
    </contact>
    <contact_backup>
      <last_name>Annalisa Berzigotti, Prof. Dr. med.</last_name>
      <phone>41 (0) 31 632</phone>
      <phone_ext>33 91</phone_ext>
      <email>annalisa.berzigotti@insel.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2018</study_first_submitted>
  <study_first_submitted_qc>January 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2018</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

